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ABSTRACT

Author: Zhang, Bin. MS
Institution: Purdue University
Degree Received: May 2018
Title: Synthesis of Ethylene Antagonists and an Anticancer DUPA Conjugate
Committee Chair: Mark Lipton
Ethylene is used by plants as a hormone to control many physiological processes throughout
the lifetime of a plant, including seed germination, growth, formation of the apical hook, organ
senescence, fruit ripening, abscission, gravitropism and responses to various stresses.1 1methylcyclopropene is the most widely used ethylene antagonist on the market currently. Studies
show that 1-alkylcyclopropene compounds react with a Cu(I) ion in the active site of ethylene
receptor 1 (ETR1) forming carbenoids and deactivating ETR1.1’2,3 There is still a great demand
for novel ethylene antagonists because 1-MCP has some drawbacks such as high volatility, low
solubility in water, and high reactivity. Our goal is to develop novel cyclopropene compounds with
fewer limitations that can be more widely used.
Several lines of evidence establish an important role for dysregulation of cellular cholesterol
homeostasis and accumulation of cholesterol in the growth of tumor cells. TO901317 and
canosimibe are potent therapeutic targets which lower intracellular cholesterol level. Our goal is
to develop targeted delivery of these two classes of agents to prostate tumor cells in order to block
the growth of prostate tumor cells in a synergistic and selective fashion. This targeting will be
effected through coupling of the cholesterol lowering agents to DUPA, a molecule designed to
target Prostate Specific Membrane Antigen (PSMA). DUPA conjugates demonstrated prostate
tumor targeting in a preliminary Phase 0 clinical trial.
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DEVELOPMENT OF NOVEL CYCLOPROPENE
COMPOUNDS AS ETHYLENE ANTAGONISTS

1.1

Introduction

Ethylene Receptor 1(ETR1)
Ethylene is used by plants as a hormone to control many physiological processes
throughout the lifetime of a plant, including seed germination, growth, formation of the apical
hook, organ senescence, fruit ripening, abscission, gravitropism and responses to various stresses1.
The molecular mechanism remained unknown until the late 1970s when the ethylene-binding site
was reported. It was proposed that plants possess a metal-containing ethylene binding site based
on a correlation of biological activity with the ability of 1-alkenes to bind to silver ion. However
the identification and characterization of the ethylene receptor was held back by inefficient
purification techniques at that time. More advanced studies discovered that ethylene and signal
transduction into the cell are carried out by a family of membrane-bound receptors, one of which
is ethylene receptor 1 (ETR1).1

Structure of ETR1
The active site of ETR1 is formed by 4 residues Asp14, Glu15, Asp57 and Lys112 (Figure
1.2). 3 Asp14, Glu15 and Asp57 form an acidic pocket. Lys112 points into this acidic pocket. Each
of these four residues at the active site has a terminal functional group which is able to coordinate
with a copper cation. Mutational analysis shows these four residues are crucial in ethylene
perception. Replacement of these residues leads to loss of ethylene perception.
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Figure 1.1 Ribbon representation of the ETR1 monomer. Asp57 is Shown by red dot3

Figure 1.2 ETR1 active site3

At an early stage in the characterization of ethylene receptors, it was discovered that the
functional unit for the receptors is a homodimer (Figure 1.3) capable of binding one ethylene
molecule per dimer. Recent studies indicate that the receptors are also able to non-covalently
associate with each other and form a cluster. Clustering of ETR1 receptors allows for
conformational changes that occur within one receptor to be propagated to other receptors in the
cluster. This provides a mechanism for signal amplification and may explain the high sensitivity
of plants to ethylene.

3

Figure 1.3 ETR1 homodimer. Asp57 is shown by red dot3

Signaling Pathway
The ethylene-binding domain of ETR1 is a homodimer containing two disulfide bonds.
Each monomer contains three transmembrane helices. When ethylene binds, the receptor
undergoes a conformational change and reaches an intermediate state (state 2 in Figure 1.4). With
ethylene bound to the active site, the intermediate state 2 is in equilibrium with state 3 which is in
a more stable conformation. The conformational change in state 3 deactivates CONSTITUTIVE
TRIPLE RESPONSE 1 (CTR1) and leads to de-repression of downstream signaling.
CTR1 is negative regulator of the pathway that acts immediately downstream from the
receptors. CTR1 inhibits downstream components of the pathway, repressing ethylene responses.
When ethylene is added, the receptors inactivate CTR1 and release downstream components from
the inhibition by CTR1.
As shown in Figure 1.5, in air, ethylene receptors maintain CTR1 in an active state that
serves to repress ethylene responses. Binding of ethylene results in a conformational change of the
receptor, which in turn causes the inactivation of CTR1. Inactivation of CTR1 releases the
repression on downstream signaling enzymes and leads to ethylene responses.

4

Figure 1.4 Schematic Depiction of the effect of ethylene binding ETR11
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Figure 1.5 Schematic depiction of ethylene signal transduction1

Ethylene Antagonist
As mentioned above, ethylene is a volatile plant hormone that hastens plants ripening,
increases enzyme activities and accelerates aging process. As ethylene speeds up the process of
plants reaching maturity and decaying, the storage and transportation of plants and fruits becomes
a problem in presence of ethylene. The control of ethylene is needed throughout the storage and
transportation of plants.
Aminoethoxyvinylglycine reduces the production of ethylene by blocking ethylene
biosynthesis. Aminoethoxyvinylglycine is fairly effective but it is too costly to be used
commercially. Aminoethoxyvinylglycine is priced at $ 1,000.00 per 100 mg commercially and is
not affordable for widespread use.

6

In order to repress the ethylene responses of plants, various ethylene antagonists were
introduced in the 1970s (Figure 1.6).4 Silver ion is a well-known ethylene antagonist, but it is
expensive, toxic and extremely environmentally unfriendly. Consequently, silver thiosulfate is not
applicable for commercial use. Several other organic compounds were also found to be ethylene
antagonists, but there were a lot of drawbacks to these compounds as well.4 The most successful
ethylene antagonist ever found is 1-methylcyclopropene (1-MCP).
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Figure 1.6

1-MCP is a very effective ethylene antagonist currently employed commercially. 1-MCP
is non-toxic and can be easily synthesized. However, there are still some drawbacks such as high
volatility, not enough solubility in water and high reactivity.7
Development of a new generation of ethylene antagonists are still needed. As more and
more research has been done in the area of the ethylene receptor, we now have a better
understanding of how these ethylene antagonists work at the ethylene receptor protein. As
mentioned before, copper ion is centered at the active site of the ethylene receptor ETR1. The
actions of 1-MCP at the ethylene binding site have been strongly linked to ring strain in the past.
But, theoretical studies of the binding of transition metals to strained alkenes have come to the
remarkable conclusion that the binding of cyclopropene is far weaker than expected because of the
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high strain energy. An alkene-metal binding which involves structural reorganization requires
strong back bonding(REF 6?). This runs counter to the theory that the strong back-bonding power of
ethylene enables it to promote signaling at the receptor6. If 1-MCP also promotes back bonding
when binding to metal ions, it should be an agonist of the ethylene receptor, not an antagonist. One
explanation for this conflict may be that 1-MCP behaves at the active of ETR1 through a different
mechanism from ethylene.

Scheme 1.12

Experiments were conducted in efforts to form complexes between copper(I) and several
different cyclopropenes2. It turned out that the only products observed were the copper-ligand
complexes and some organic products. Evidence in favor of a carbenoid intermediate was obtained
by trapping it with an alkene (Scheme 1.1). The copper ion at the ethylene receptor’s active site
can convert 1-alkylcyclopropene to a carbenoid intermediate, which can irreversibly react with a
neighboring protein residue and lead to an inactivated receptor (Scheme 1.1).2

9

Figure 1.7 Synthetic Ethylene Antagonists. Solubility at pH 7: blue, highly soluble; pink,
soluble; black, moderately soluble; gray, N/A

Knowing the theory, cyclopropene derivatives ring have been made and tested, but none
of them shows higher activity than 1-MCP (Figure 1.7).7 Since a number of drawbacks limit the
usage of 1-MCP, there is still great demand for novel ethylene antagonists. High stability, high
water solubility, long lasting protection, open space application, and environmental acceptance are
also required for new ethylene antagonists.
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1.2

Synthetic Routes & Results
Due to these drawbacks of the currently available ethylene antagonists and the demand for

a new generation of ethylene antagonists, new candidates were designed for synthesis. The original
synthetic proposal was provided by our funding agency (Scheme 1.2). These candidates all contain
a constrained cylopropene ring. To improve the solubility in water, hydrophilic functional groups
are installed as well.
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Scheme 1.2 Originally proposed synthetic route

Original Synthetic Route
At the starting phase this project, we followed the original synthesis proposal and started
with enolization of 2,4-pentadione with sodium hydride as base and alkylation with 2,3dibromopropene to get 1. Only a trace of 1 was observed after this reaction. Several other strong
bases were tried in this enolate reaction, yet none of them gave the product 1. We were not able to
recover 2,4-pentadione after the reaction. It was probably because that 2,4-pentadione was too
acidic. In the presence of the weak base potassium carbonate, the reaction afforded 1 in 36% yield,
which was still low. To improve the yield, we put 1 eq. 18-crown-6 in the reaction to make the
enolate more nucleophilic. However, it turned out that 18-crown-6 did not improve the yield.
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Scheme 1.3

Cyclopropanation of 1 using Phase Transfer Catalyst (PTC) benzyltributylammonium
chloride (BTBAC) to get 19 did not give any product . Neither product nor starting material was
recovered after the PTC reaction. Then we tried cylopropanation with KOtBu/CHBr3, but the
reaction did not work either (Scheme 1.3). We ran several test reactions on cyclohexene to see if
these reaction conditions work on an aliphatic alkene as well as to figure out if there are other ways
to do the cylopropanation reaction (Table 1.1).
The PTC reaction with cyclohexene as starting material did give the desired product in 62%
yield. The KOtBu reaction also gave the desired product, but the yield was only 28%. We thought
the reason why the same conditions did not work on 1 was that there was an α-acidic proton that
could ionize in the basic reaction conditions. To remove the acidic proton, we had to protect the
two carbonyl groups. We decided to reduce the two carbonyl groups in to alcohols because we
thought the diol 6 could be water soluble and a very interesting compound to test.
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Table 1.1 Cyclopropenation

Entry

SM

Base

Reaction Conditions

1

Cyclohexene
Cyclohexene
Cyclohexene

NaOH(50% in
water)
KOtBu
KOH

4

Cyclohexene

NaOEt

5

Cyclohexene

NaOMe

BTBAC, CH2Cl2, rt,
24h
Hexanes, ‐10°C, 2h
CH2Cl2, rt, 24h
CH2Cl2, EtOH, 0°C,
24h
CH2Cl2, MeOH, 0°C,
24h

2
3

Yield(%)
62
28
35
11
7

1 was reduced by sodium borohydride to afford diol 2 in 70% yield. The diol 2 was a
mixture of syn and anti stereoisomers and was used in next reaction without further purification.
To keep the alcohols groups from reacting with the carbene intermediate in the next reation, 2 was
reacted with 2,2-dimethoxypropane giving acetonide 3 with a yield of 36%, which was not high.
43% of 2 was recovered after the reaction, which indicates the reaction was not complete. The low
yield and incompleteness may be due to the impure 2,2-dimethoxypropane. Thus, this reaction was
run at room temperature and probably higher temperature would improve the yield. Since enough
material was obtained, we moved on with what we got. Having the acidic proton taken care of, 3
was treated with NaOH in presence of phase transfer catalyst giving 4 in 50% yield.
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Scheme 1.4 Overall synthesis towards 7

4 was treated with methyl lithium in ether to afford 5, followed by deprotection of the
acetonide giving 6 at 21% yield over two steps. The ether we used in methyl lithium reaction was
not dry enough, which lead to incomplete conversion of 4 to 5 and low yield. However, in the last
step, we failed to oxidized diol 6 to 7. Considering that oxidation at the last step of a synthetic
route could be problematic, we think we need to come up with a new strategy to synthesize 7.

Scheme 1.5
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To synthesize 12, we started with dimethyl malonate. Dimethyl malonate was treated with
sodium hydride to form a enolate, followed by the addition 2,3-dibromopropene giving 8 in 58%
yield. 8 was treated with 50% NaOH (w/v in water) and the phase transfer catalyst. The desired
product was not observed. Instead we got a hydrolyzed product (Scheme 1.5). 8 was hydrolyzed
in basic condition in the presence of water. Since methyl esters are easily hydrolyzed, we replaced
the methyl groups with isopropyl groups to improve the resistance to hydrolysis. We also tested
the esters in various cyclopropanation reaction conditions (Table 1.2). The best reaction conditions
we found were potassium hydroxide power in dry dichloromethane with the diisopropyl ester,
which gave product in a 35% yield.

Table 1.2 Cyclopropanation of Malonates
Entry

SM

Reation Condition

Result

Yield(%)

1

8

NaOH(50% in water), PTC,
DCM, rt, 24h

Hydrolyzed

--

2

8

KOH, DCM, rt, 24h

SM consumed, No
product

--

3

8

KOtBu, Hexanes, -10°C, 2h

SM recovered

--

4

9

NaOH(50% in water), PTC,
DCM, rt, 24h

SM consumed, trace of
product observed

--

5

9

KOH, DCM, rt, 24h

afforded desired product

35

Treatment of 10 with methyl lithium gave trace amonts of 11 (~0.2 mg, 4%). Several trials
of this reaction were performed. In some of those trials, large amounts of starting material 10 were
observed after each trial while in one trial, neither starting material nor product was observed due
to too many equivalents of methyl lithium added to the reaction. Part of the reason may be that our
ether was not dry enough. The acidic proton in 10 may account for the low yield, too. Apart from
that, using proper equivalence of methyl lithium is also crucial. We are still working on making
11a at current stage. The last step of synthesis towards 12 is to hydrolyze the diisopropyl ester in
11a to give carboxylic acid.
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Scheme 1.6 Overall synthesis towards 12

The originally proposed synthesis of 18 started with 2-butanone (Scheme 1.7). The
drawback of this methodology is that deprotonation could happen at either side of the ketone group.
This reaction may generate two isomers. Besides, the pKa of 2-butanone is very high and harsh
reaction conditions are required.

Scheme 1.7
Test reactions of 2-butanone with methyl iodide were conducted (Table 1.3). LiHMDS is a
very hindered base and prefer to deprotonate the less hindered side giving the kinetic product. It is
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not surprising to see that no desired product form with LiHMDS. The sodium hydride prefers
thermodynamic product at low temperature in theory. However, the test reaction gave a very low
yield.

Table 1.3

Entry

SM

Reation Condition

Yield(%)

1

2‐butanone

LiHMDS, THF, ‐78°C to rt., o/n

0

2

2‐butanone

NaH, THF, 0°C to rt., 6h

7

We came up with a different synthesis towards 18 starting with methyl acetoacetate
(Scheme 1.8). 13 was made from methyl acetoacetate by enolate reaction in 64% yield. The 2bromopropene group was installed by enolate reaction as well in a 42% yield. The methyl ester
was hydrolyzed to a carboxylic acid under basic conditions, followed by decarboxylation giving
16. Several decarboxylation reactions were performed but none of them was successful.
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Scheme 1.8

Revised synthetic Route
In the previous route, we found that cyclopropanation after enolate reaction could be
problematic. Thus, carbonyl groups can not suvive MeLi condition in which tribromocyclopropane
compounds were converted to cyclcopropene compounds. We think we need to employ a new
strategy in which cyclopropene compounds were synthesized first and then added onto ketones or
esters later on through enolate reaction.

18
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Scheme 1.9

In this route, we started with cyclopropanecarboxylic acid, 19. A phenylselenyl substituent
(PhSe-) was added onto the cyclopropane ring of methyl ester 20. However, after H2O2 oxidation
of 21, desired product 22 was not observed. We think that constrained cyclopropape ring might
prohibit the elimination. The selenoxide intermediate does not get access to the adjacent proton,
therefore elimination could not proceed.

Second Revised Synthetic Route
Failure to synthesize cyclopropene compound through phenylselenyl route led us to return to
the MeLi strategy. In this route, we propose to synthesize dibromocylcoprane compounds first by
the procedure developed by Charette8-10, followed by MeLi reduction in order to get cyclopropene
compounds.

19

Scheme 1.10

The primary bromide in 2,3-dibromopropene (Scheme 1.10) was converted to an alcohol
in the presence of silver nitrate and water to afford 24. Dibromocyclopropane 25 was synthesized
by following the procedure developed by Charette and coworkers.8-10 Cyclopropene 26 was
obtained by MeLi reduction. We failed to convert the alcohol group of 26 into an iodide. Starting
material was consumed and no desired product was observed after subjecting 26 to Appel
conditions. It was suspected that the cyclopropene ring was opened under such Appel condition.
More efforts are needed to figure out what was made.
25 was treated with Appel condition to generate 28 (Scheme 1.11), followed by MeLi
reduction to afford 29. We proposed that 29 could be used as electrophile in enolate reaction to
generate final products. However, 29 did not reaction with any nucleophile we tested. Then we
proposed to use 30a instead in the enolate reaction. In order to get 30a, 28 was first treated with 2
eq. of MeLi, followed by quench with iodine. The major product of this reaction is 30b and only
trace of the desired product was observed. The highest ratio of 30a/30b we could get was 5/95.
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Scheme 1.11

Failure to synthesize cyclopropene fragments first and couple them onto enolates led back
to the strategy in which bromocyclopropanes were coupled onto enolates first. We successfully
made 4b (Scheme 1.12). A number of reducing reagents such as SmI2, Mg, Zn dust and Na/Hg
were tried on 4b but none of them gave the desired product 7.

21

Scheme 1.12

28 was reacted with dimethyl malonate to generate diester 10b, which was then hydrolyzed
to afford 7. 7 was treated with excess amount of MeLi to afford the final product 12.

1.3. Conclusion
We have tried several synthetic routes toward the designed ethylene antagonists, but none
of these synthetic routes is successful. Only one of the desired compounds was synthesized. Each
synthetic route has some limitations and drawbacks as mentioned before. More efforts are needed
to finish the compounds. Although we failed to complete the synthesis of most desired
cyclopropene

compounds,

we

have

developed

several

strategies

to

synthesize.

22
dibromocyclopropanes and tribromocyclopropanes, which are important precursor of
cyclopropene.

Figure 1.87
We think more research could be done in the future study of this project. Some docking
study could be done on the ethylene receptor protein ETR1. Although the mechanism of ethylene
antagonists repressing ethylene responses is different from normal inhibition of proteins, it might
be worthwhile to study the interaction and affinity between substrate and protein binding site.
There are some interesting compounds repressing ethylene responses effectively (Figure 8).7 These
compounds all have a long linear alkyl tail attached to cyclopropene. Docking study of these long
tail cyclopropenes with ETR1 might reveal if the length of the alkyl tail is important or not.
Modification of the terminal of alkyl tails into more electrophilic functional groups should also be
studied .
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CHAPTER 2. SYNTHESIS OF A DUPA CONJUGATE

2.1.

Introduction
Collaborative studies in several Purdue University Center for Cancer Research laboratories

has demonstrated that the levels of cholesterol sulfate, an important derivative of cholesterol, are
dramatically upregulated in human prostate neoplasia.6 These findings and other experimental data
suggest that selective attenuation of cholesterol, cholesterol sulfate, and other cholesterol
metabolite levels in prostate cancer (Pca) may be a promising avenue to block their growth.6
Specifically, recent studies in the Cheng laboratory have demonstrated that cholesterol ester
formation mediated by the enzyme ACAT (acyl-CoA:cholesterol acyltransferase) plays an
important role in the intracellular accumulation of cholesterol esters in PCa.6 In accord with this
observation and the key role of cholesterol in tumor cells, treatment of the LNCaP human PCa cell
line with the ACAT inhibitor avasimibe (Scheme 2.1) blocks their growth. In a related approach,
Crist and coworkers have demonstrated that the accumulation of cholesterol sulfate in prostate
cancer is associated with increased levels of cholesterol sulfotransferase (SULT) 2B1b, an enzyme
that can regulate LXR (Liver X receptor) activity, a key regulator of cholesterol homeostasis, by
sulfonation of endogenous LXR agonists (oxycholesterols).1-3 The Crist laboratory showed that
genetic knock down of SULT2B1b in LNCaP suppresses growth by activating LXR. The growth
inhibitory effects of LXR activation in several cancers including prostate is shown to be due to
upregulation of the transporters ABCA1 and ABCG1, which are key mediators of cholesterol
efflux, and down regulation of LDLR, a receptor responsible for cholesterol uptake. These and
previous studies establish that activation of LXR either genetically or by treatment with the nonsteroidal LXR agonist TO901317 is a potent therapeutic target in PCa via reduction of intracellular
cholesterol. Unfortunately, animal testing and limited human trials using systemic dosing of
TO901317 show profound, deleterious elevations in serum cholesterol and triglycerides,
precluding systemic therapeutic use. On the other hand, ACAT inhibitors including both avasimibe
and canosimibe have been developed and have demonstrated effective cholesterol lowering in
human clinical trials. It is the hypothesis of this proposal that targeted delivery of these two classes
of agents to prostate tumor cells will block their growth in a synergistic and selective fashion. This
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targeting will be approached through coupling of the cholesterol lowering agents to the prostate
specific membrane antigen (PSMA) ligand DUPA.

F3C CF3
O

S

OH

O

iPr

N
CF3

iPr

TO901317

iPr
O O O
S
N
H
Avasimbe

OH
N
F

O

O

H
N

OH OH
N
H

O

OH
OH OH

Canosimibe

Scheme 2.1

The Low laboratory has demonstrated that the folate receptor (FR) is overexpressed on
many epithelial cancers and they have exploited for targeted delivery of folate-linked liposomes
to cancer cells in vitro7. The Low laboratory more recently has developed a DUPA-targeting
reagent (Figure 2) that binds prostate specific membrane antigen (PSMA) with high affinity. This
targeting ligand has now been utilized to develop a radioligand for prostate tumor cells (EC0652;
Figure2) in Phase 0 clinical trials for prostate cancer diagnosis (8). The DUPA-targeting reagent
has also been attached to tubulysin to generate a PSMA-targeted cytotoxic agent (EC1069; Figure
2) with very promising activity in mouse prostate cancer models (9).
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Scheme 2.2
2.2 Synthesis
The synthesis started by reacting commercially available starting material mecaptoethanol
(31) with 2,2’-dithiodipyridine (32) to afford 33. TO901317 was reacted with phosgene to afford
35, which was used in the next reaction without any purification. Crude 35 was reacted with 33 to
afford 37 in 43% yield over 2 steps. Then 37 and DUPA (38) were coupled through disulfide
formation to afford the final product DUPA-TO901314 conjugate (39).
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Scheme 2.3
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2.3 Conclusion
We have coupled TO901317, a commercially availabe LXR agonist, to the PSMA ligand
DUPA. The structure and purity of the DUPA-TO901317 conjugate (39) was confirmed by
MALDI mass spectrum and HPLC. Biological evaluation of DUPA-TO901317 conjugate will be
conducted in a future study.
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APPENDIX A: EXPERIMENTAL PROCEDURES

Solvents were purified by passage through an activated chromatography prior to use*. Reverse
phase HPLC was performed using a Gilson Model 116 with HPLC grade acetonitrile (CH3CN)
and deionized water (H2O) containing 0.1% of trifluoroacetic acid. Flash chromatography was
performed using 230-400 mesh silica gel. Matrix assisted laser desorption ionization time-of-flight
mass spectrometry (MALDI-TOF-MS) was performed using an Applied Biosystems.

____________________
*Solvent chromatographys are composed of activated alumina and supported copper redox catalyst
reactant. See: organometallics 1996, 15, 1518-1520
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3-(2-bromoallyl)pentane-2,4-dione (1). 2,3-Dibromopropene (0.2 mL, 1.74 mmol) was
added to a suspention of K2CO3 (228 mg, 1.65 mmol) and 2,4-pentanedione (0.1 mL, 1 mmol) in
acetone (5 mL). The reaction mixture was refluxed overnight and then filtered. The filtrate was
concentrated under reduced pressure and purified by flash chromatography (10/90 EtOAc/Hexanes)
to yield 1 as a yellow oil (138 mg, 0.63 mmol, 36%). 1H NMR (300 MHz, Chloroform-d) δ 5.74
– 5.32 (m, 2H), 3.37 (t, J = 1.7 Hz, 1H), 2.24 (s, 0H), 2.13 (s, 2H) ppm.

3-(2-bromoallyl)pentane-2,4-diol (2). To a solution of NaBH4 (119 mg, 3.1mmol) in 0.5 M
aq. NaOH (3 mL) was added 1 (312 mg, 1.4mmol) over a period of 1 h at 0oC. The reaction mixture
was neutralized with 2.0 M aq. HCl, neutralized with sat. aq. NaHCO3 and concentrated under
reduced pressure. The resulting material was extracted with Et2O (3x). The organic layers were
combined, dried over MgSO4, concentrated under reduced pressure and purified by flash
chromatography (20/80EtOAc/Hexanes) to yield 2 as a colorless oil (224 mg, 1.0 mmol, 70%). 1H
NMR (300 MHz, Chloroform-d) δ 5.78-5.40 (m, 2H), 4.55- 3.90 (m, 2H), 2.76-2.3 (m, 2H), 1.371.05 (m, 6H) ppm.
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5-(2-bromoallyl)-2,2,4,6-tetramethyl-1,3-dioxane (3). To a solution of 2 (224 mg, 1.0 mmol)
in CH2Cl2 (15 mL) was added camphorsulfonic acid (23 mg, 0.1 mmol) and 2,2Dimethoxypropane (2.45 mL, 20.0 mmol). The reaction mixture was stirred at room temperature
overnight and then quenched with sat. aq. NaHCO3. The resulting mixture was extracted with
CH2Cl2 (3x). The organic layers were combined, dried over MgSO4, concentrated under reduced
pressure and purified by flash chromatography (10/90 EtOAc/Hexanes) to yield 3 as a colorless
oil (96 mg, 0.37 mmol, 36%). 1H NMR (300 MHz, Chloroform-d) δ 5.75 – 5.26 (m, 2H), 4.26 –
3.39 (m, 2H), 2.74 – 2.24 (m, 2H), 1.92 – 1.06 (m, 12H) ppm.

2,2,4,6-tetramethyl-5-((1,2,2-tribromocyclopropyl)methyl)-1,3-dioxane (4). 50% w/v
NaOH (0.4 mL) was added dropwise to a solution of bromoform (0.5 mL, 5.6 mmol),
benzyltributylammonium chloride (50 mg, 0.16 mmol) and 3 (96 mg, 0.37 mmol) in CH2Cl2 (0.4
mL). The reaction mixture was stirred at room temperature overnight and then poured onto ice
water. The resulting mixture was extracted with CH2Cl2 (3x). The organic layers were combined,
dried over MgSO4, concentrated under reduced pressure and purified by flash chromatography
(5/95 EtOAc/Hexanes) to yield 4 as an orange oil (79 mg, 0.18 mmol, 50%). 1H NMR (300 MHz,
Chloroform-d) δ 4.24 – 3.62 (m, 4H), 3.53 (q, J = 7.0 Hz, 2H), 1.81 – 1.31 (m, 1H), 1.23 – 0.91
(m, 12H) ppm.
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5-(cycloprop-1-en-1-ylmethyl)-2,2,4,6-tetramethyl-1,3-dioxane (5). At -78oC, a solution of
1.6 M MeLi in Et2O (0.46 mL, 0.73 mmol) was added to a solution of 4 (79mg, 0.18 mmol) in
Et2O (2 mL). The reaction mixture was stirred at -78 oC for 15 min, then warmed up to 0oC and
stirred for 15 min. The reaction was quenched with sat. aq. NH4Cl at 0oC. The resulting mixture
was extracted with CH2Cl2 (3x). Organic layers were combined, dried over MgSO4, and
concentrated under reduced pressure and purified by flash chromatography (10/90 EtOAc/Hexanes)
to yield product 5 as a colorless oil (18 mg, 0.09 mmol, 50%). 1H NMR (300 MHz, Chloroformd) δ 7.63 (m, 1H), 4.47 – 3.87 (m,2H), 3.84 – 3.60 (m, 2H), 2.01 – 1.79 (m, 2H), 1.25 (m, 12H)
ppm.

3-(cycloprop-1-en-1-ylmethyl)pentane-2,4-diol (6). 5 (17 mg, 0.09 mmol) was dissolved in
AcOH/H2O (4 mL/1 mL). The reaction mixture was stirred for 3 h and then neutralized with aq.
NaHCO3. The resulting mixture was extracted with CH2Cl2 (3x). Organic layers were combined,
dried over MgSO4, concentrated under reduced pressure and purified by flash chromatography
(20/80 EtOAc/Hexanes) to yield product 6 as a colorless oil (6 mg, 0.04 mmol, 44%). 1H NMR
(300 MHz, Chloroform-d) δ 6.57 (ddd, J = 3.1, 1.8, 1.2 Hz, 1H), 4.02 – 3.82 (m, 2H), 2.56 (dd, J
= 4.1, 1.3 Hz, 2H), 1.95 – 1.63 (m, 1H), 1.20 (dd, J = 6.1, 1.2 Hz, 3H), 0.99 – 0.94 (m, 3H) ppm.
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Dimethyl 2-(2-bromoallyl)malonate (8). Dimethyl malonate (0.72 mL, 6.3 mmol) was added
dropwise to a suspension of NaH (158 mg, 6.3 mmol) in THF (5 mL) at 0oC. After 15 min, 2,3Dibromopropene (0.6 mL, 5.2 mmol) was added to the reaction. The reaction was warmed up to
room temperature and monitored by TLC. After the reaction was complete, the reaction was
quenched with sat. aq. NH4Cl. The resulting mixture was extracted with Et2O (3x). Organic layers
were combined, dried over MgSO4, concentrated under reduced pressure and purified by flash
chromatography (5/95 EtOAc/Hexanes) to yield product 8 as a yellow oil (764 mg, 3.0 mmol,
58%). 1H NMR (300 MHz, Chloroform-d) δ 5.69 (dq, J = 2.0, 1.0 Hz, 1H), 5.48 (d, J = 1.9 Hz,
1H), 3.83 (t, J = 7.5 Hz, 1H), 3.76 (s, 6H), 3.02 (dd, J = 7.5, 1.0 Hz, 2H) ppm.

Diisopropyl 2-(2-bromoallyl)malonate (9). 8 (763 mg, 3 mmol) and Titanium isopropoxide
(1 mL, 3.4 mmol) was added to isopropanol (15 mL). The reaction mixture was stirred for 3h. H2O
(15 mL) was added to the reaction. The resulting mixture was stirred for 30min and then filtered.
The filtrate was extracted with CH2Cl2 (3x). The organic layers were combined, dried over MgSO4,
concentrated under reduced pressure and purified by flash chromatography (10/90 EtOAc/Hexanes)
to yield product 9 as a colorless oil (403 mg, 1.4 mmol, 43%). 1H NMR (300 MHz, Chloroformd) δ 5.67 (s, 1.1 Hz, 1H), 5.46 (s, 1H), 5.05 (pd, J = 6.3, 1.1 Hz, 2H), 3.70 (td, J = 7.6, 1.1 Hz, 1H),
2.98 (dt, J = 7.6, 1.1 Hz, 2H), 1.24 (ddd, J = 6.3, 2.2, 1.1 Hz, 12H) ppm.
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Diisopropyl 2-((1,2,2-tribromocyclopropyl)methyl)malonate (10). Bromoform (1.35 mL,
15 mmol) was added to a suspension of 9 (210 mg, 0.7 mmol) and KOH (840 mg, 15 mmol) at 10oC. The reaction mixture was stirred at -10oC for 1.5 h and then stirred at room temperature
overnight. H2O was added to quench the reaction. The resulting mixture was extracted with CH2Cl2
(3x). The organic layers were combined, washed with brine, dried over MgSO4, concentrated under
reduced pressure and purified by flash chromatography (5/95 EtOAc/Hexanes) to yield product 10
as a orange oil (121 mg, 0.25 mmol, 36%).1H NMR (300 MHz, Chloroform-d) δ 6.26 (d, J = 1.2
Hz, 1H), 5.10 (hd, J = 6.3, 1.2 Hz, 2H), 3.39 (d, J = 1.2 Hz, 2H), 2.56 – 1.79 (m, 2H), 1.30 (ddd,
J = 6.3, 3.1, 1.1 Hz, 16H) ppm.

Methyl 2-acetyl-4-bromo-2-methylpent-4-enoate (14). 13 (589 mg, 4.5 mmol) was added to a
suspension of NaH (217 mg, 5.4 mmol) in THF (15 mL) at 0oC. After 15 min, 2,3-Dibromopropene
(0.62 mL, 5.4 mmol) was added to the reaction. The reaction was warmed up to room temperature
and monitored by TLC. After the reaction is completed, the reaction was quenched with sat. aq.
NH4Cl. The resulting mixture was extracted with Et2O (3x). Organic layers were combined, dried
over MgSO4, concentrated under reduced pressure and purified by flash chromatography (10/90
EtOAc/Hexanes) to yield product 10b as a yellow oil (710 mg, 2.85 mmol, 63%). 1H NMR (300
MHz, Chloroform-d) δ 5.58 – 5.36 (m, 2H), 3.67 (d, J = 3.6 Hz, 3H), 3.17 – 2.75 (m, 2H), 2.10 (s,
3H), 1.34 (s, 3H) ppm.
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2-acetyl-4-bromo-2-methylpent-4-enoic acid (15). 14 (237 mg, 1.0 mmol) was added to a
solution of LiOH (72 mg, 3.0 mmol) in THF/H2O (3 mL/1 mL). The reaction mixture was stirred
overnight and then diluted with 0.1 M aq. NaOH (5 mL). The resulting solution was washed with
CH2Cl2 (3x), acidified by 1.0 M aq. HCl, and extracted with EtOAc (3x). The organic layers was
combined, dried over MgSO4 and concentrated under reduced pressure to yield 15 as a colorless
oil (86 mg, 0.37 mmol, 97%). 15 was carried on to next step without further purification. 1H NMR
(300 MHz, Chloroform-d) δ 11.31 (s, 1H), 5.64 (s, 1H), 5.51 – 5.43 (s, 1H), 3.00 – 2.34 (m, 2H),
2.08 (s, 3H), 1.20 (d, J = 6.7 Hz, 3H) ppm.

Methyl cyclopropanecarboxylate (20). To a solution of cyclopropanecarboxylic acid (0.5
mL, 6.3 mmol) in MeOH (10 mL) was added a few drops of conc. sulfuric acid. The mixture was
refluxed overnight, after which time it was concentrated to remove MeOH. The residue was diluted
with CH2Cl2 (10 mL) and washed with sat. NaHCO3 (2 x 10 mL), then H2O (2 x 10 mL). The
organic layer was dried over MgSO4 and concentrated under reduced pressure to yield 20 as a
slightly yellow oil (540 mg, 5.4 mmol, 87%). 1H NMR (300 MHz, Chloroform-d) δ 3.68 (d, J =
0.4 Hz, 3H), 1.68 – 1.54 (m, 1H), 1.06 – 0.78 (m, 2H) ppm.
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Methyl 1-(phenylselanyl)cyclopropane-1-carboxylate (21). A solution of 1.5 M BuLi
( 0.206 mL, 0.33 mmol) was added dropwise to a solution of diisopropylamine ( 0.05 mL, 0.36
mmol) in THF at -78 oC. The reaction mixture was warmed up to 0 oC and stirred for 30 min. 20
was added to the reaction at -78 oC. The reaction mixture was stired at -78 oC for 30 min and then
stirred at 0 oC for another 30 min. PhSeBr ( 71 mg, 0.30 mmol) was added to the reaction at -78
o

C. The reaction mixture was warmed up to 0 oC and stirred for 30 min. The reaction mixture was

quenched with sat. aq. NH4Cl at 0 oC. The resulting mixture was extracted with CH2Cl2 (3x). The
organic layers were combined, dried over MgSO4 and concentrated under reduced pressure to
yield crude 21, which was carried on to next step without further purification. Crude 21 was treated
with 30% H2O2. The resulting mixture was extracted with CH2Cl2 (3x). Organic layers were
combined, dried over MgSO4, concentrated under reduced pressure and purified by flash
chromatography (10/90 EtOAc/Hexanes). No desired product 22 was observed and a small amount
of 21 was recovered as colorless oil (20 mg, 0.78 mmol, 26%). 1H NMR (300 MHz, Chloroformd) δ 7.53 – 7.26 (m, 4H), 3.71 (s, 3H), 1.80 – 1.70 (m, 2H), 1.37 – 1.29 (m, 2H) ppm.

2-bromoprop-2-en-1-ol (24). To a solution of AgNO3 (1.7 g, 10 mmol) in H2O (20 mL) was
added DMSO (40 mL), followed by 2,3-dibromopropene (0.57 mL, 5.0 mmol). The reaction
mixture was stirred overnight at room temperature. 3.0 M aq. NaOH (3.5 mL) was added to the
reaction mixture. The resulting mixture was filtered. The filtrate was poured onto ice (20 g),
extracted with Et2O (3x). The organic layers were combined, dried over MgSO4, concentrated
under reduced pressure and purified by flash chromatography (20/80 Et2O/Pentane) to yield 24 as
a colorless oil (631 mg, 4.6 mmol, 92%). 1H NMR (300 MHz, Chloroform-d) δ 5.93 (q, J = 1.7
Hz, 1H), 5.58 (dt, J = 2.1, 1.1 Hz, 1H), 4.22 (t, J = 1.3 Hz, 2H), 2.20 (s, 1H) ppm.

38

(1,2-dibromocyclopropyl)methanol (25). 2,2,2-Trifluoroethanol (0.6 mL, 6.4 mmol) was
slowly added to a solution of Et2Zn (0.8 mL, 6.4 mmol) in CH2Cl2 (5 mL) at 0oC, followed by
bromoform (0.7 mL, 6.4 mmol). The reaction mixture was stirred for 5 min at 0oC. 24 (190mg, 1.4
mmol) was added to the reaction mixture. The reaction mixture was warmed to room temperature
and stirred overnight. The reaction mixture was quenched with sat. aq. NH4Cl. The resulting
mixture was extracted with CH2Cl2 (3x). Organic layers were combined, dried over MgSO4,
concentrated under reduced pressure and purified by flash chromatography (15/85 EtOAc/Hexanes)
to yield 25 as a yellow oil (150 mg, 0.65 mmol, 47%). 1H NMR (300 MHz, Chloroform-d) δ 3.95
– 3.57 (m, 2H), 3.05 (ddd, J = 8.7, 5.8, 0.8 Hz, 1H), 1.95 (t, J = 6.4 Hz, 1H), 1.69 (ddd, J = 8.7,
8.0, 0.8 Hz, 1H), 1.34 (dd, J = 8.1, 5.8 Hz, 1H) ppm.

Cycloprop-1-en-1-ylmethanol (26). At -78oC, a solution of 1.3 M MeLi in Et2O (1.2 mL, 1.6
mmol) was added to a solution of 28 (95 mg, 0.4 mmol) in Et2O (4 mL). The reaction mixture was
stirred at -78 oC for 1, then warmed up to 0 oC and stirred for 30 min. The reaction was quenched
with sat. aq. NH4Cl at 0 oC. The resulting mixture was extracted with Et2O (3x). Organic layers
were combined, washed with H2O, dried over MgSO4, and concentrated carefully under reduced
pressure to yield crude product 26 as a colorless volatile liquid (23 mg, 0.33 mmol, 80%). 26 was
carried on to next step without further purification. 1H NMR (300 MHz, Chloroform-d) δ 6.78 (m,
1H), 4.67 (s, 2H), 1.10 (s, 2H) ppm.
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1,2-dibromo-1-(iodomethyl)cyclopropane (28). To a solution of Ph3P (38 mg, 0.14 mmol) in
CH2Cl2 (2 mL) was added imidazole (10 mg, 0.14 mmol) and I2 (37 mg, 014 mmol). After I2 was
dissolved, a solution of 25 (30 mg, 0.13 mmol) was added. The reaction stirred at room temperature
for 2 h. The reaction mixture was concentrated under reduced pressure. The resulting material was
diluted with Et2O (2 mL) and then filtered. The filtrate was concentrated under reduced pressure,
followed by flash chromatography (10/90 EtOAc/Hexanes) to yield 28 as a colorless oil (37 mg,
0.11 mmol, 84%).1H NMR (300 MHz, Chloroform-d) δ 3.82 – 3.52 (m, 2H), 3.13 – 2.89 (m, 1H),
1.84 – 1.49 (m, 2H) ppm.

1-bromo-2-methylenecyclopropane (29). At -78 oC, a solution of 1.3 M MeLi in Et2O (0.58
mL, 0.75 mmol) was added to a solution of 28 (250 mg, 0.75 mmol) in Et2O (4 mL). The reaction
mixture was stirred at -78 oC for 30 min, then warmed up to 0 oC. The reaction was quenched with
sat. aq. NH4Cl at 0 oC. The resulting mixture was extracted with Et2O (3x). Organic layers were
combined, washed with H2O, dried over MgSO4, and concentrated carefully under reduced
pressure to yield crude product 29 as a colorless volatile liquid (91mg, 0.68 mmol, 91%). 29 was
carried on to next step without further purification. 1H NMR (300 MHz, Chloroform-d) δ 5.82 (td,
J = 2.9, 1.0 Hz, 1H), 5.65 (dt, J = 2.4, 1.9 Hz, 1H), 3.52 – 3.45 (q, J = 5.2 Hz, 1H), 1.85 (dddd, J
= 10.7, 7.9, 2.7, 2.0 Hz, 1H), 1.49 (dddd, J = 11.0, 3.9, 3.1, 2.4 Hz, 1H) ppm.
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1-(iodomethyl)cycloprop-1-ene (30a) & 1-iodo-2-methylenecyclopropane (30b). At -78 oC,
a solution of 1.3 M MeLi in Et2O (0.88 mL, 1.15 mmol) was added to a solution of 28 (334 mg,
1.0 mmol) in Et2O (5 mL). The reaction mixture was stirred at -78 oC for 30 min and then warmed
up to 0 oC and stirred for 10 min. The reaction mixture was re-cooled down to -78 oC and I2 (292
mg, 1.15 mmol) was added to the reaction mixture. The reaction mixture was warmed up to room
temperature and then quenched with sat. aq. NH4Cl. The resulting mixture was extracted with Et2O
(3x). Organic layers were combined, washed with H2O, dried over MgSO4, and concentrated under
reduced pressure to yield a mixture of 30a and 30b as a colorless oil (63 mg, 0.17 mmol, 64%).
30a and 30b were carried on to next step without further purification. The ration of 30a/30b was
determined by NMR.

3-((1,2-dibromocyclopropyl)methyl)pentane-2,4-dione (4b). 28 (50 mg, 0.15 mmol) was
added to a suspention of K2CO3 ( 21 mg, 0.15 mmol) and 2,4-Pentanedione (0.1 mL, 1 mmol) in
acetone (5 mL). The reaction mixture was refluxed overnight and then filtered. The filtrate was
concentrated under reduced pressure and purified by flash chromatography (10/90 EtOAc/Hexanes)
to yield 4b as a yellow oil (24 mg, 0.077 mmol, 15%). 1H NMR (300 MHz, Chloroform-d) δ 5.40
(s, 1H), 4.15 – 3.97 (m, 2H), 3.13 (dd, J = 8.9, 6.0 Hz, 1H), 2.28 (s, 3H), 2.16 (s, 3H), 1.80 (dd, J
= 8.9, 8.1 Hz, 1H), 1.39 (dd, J = 8.2, 6.0 Hz, 1H) ppm.
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dimethyl 2-((1,2-dibromocyclopropyl)methyl)malonate (10b). Dimethyl malonate (0.057
mL, 0.5 mmol) was slowly added to a suspension of NaH (24mg, 0.6 mmol) in THF (5 mL) at 0
o

C. After 15 min, 28 (167mg, 0.5 mmol) was added to the reaction.The reaction was warmed up

to room temperature and stirred for 2 h. The reaction was quenched with sat. aq. NH4Cl. The
resulting mixture was extracted with CH2Cl2 (3x). Organic layers were combined, dried over
MgSO4, concentrated under reduced pressure and purified by flash chromatography (10/90
EtOAc/Hexanes) to yield crude product 10b as a yellow oil (94 mg, 0.27 mmol, 55%). 1H NMR
(300 MHz, Chloroform-d) δ 3.94 (ddd, J = 8.6, 6.1, 0.7 Hz, 1H), 3.78 (dt, J = 13.9, 0.6 Hz, 6H),
2.92 (ddd, J = 8.8, 5.9, 0.7 Hz, 1H), 2.59 – 2.14 (m, 2H), 1.61 – 1.52 (m, 1H), 1.33 – 1.23 (m,
1H) ppm.

2-((1,2-dibromocyclopropyl)methyl)malonic acid (11b). To a solution of 10b (94 mg, 0.27
mmol) in THF/MeOH (2 mL/1 mL) was added 3.0 M aq. NaOH (0.5 mL). The reaction mixture
was stirred overnight and then diluted with 0.1 M aq. NaOH (5 mL). The resulting solution was
washed with CH2Cl2 (3x), acidified by 1.0 M aq. HCl, and extracted with EtOAc (3x). The organic
layers was combined, dried over MgSO4 and concentrated under reduced pressure to yield 11b as
a colorless oil (86 mg, 0.27 mmol, 97%). 1H NMR (300 MHz, Chloroform-d) δ 4.04 (t, J = 7.1 Hz,
1H), 2.97 (dd, J = 8.8, 6.0 Hz, 1H), 2.43 (ddd, J = 67.2, 15.0, 7.1 Hz, 2H), 1.63 (t, J = 8.5 Hz, 1H),
1.41 – 1.30 (m, 1H) ppm.
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2-(cycloprop-1-en-1-ylmethyl)malonic acid (12). At -78oC, a solution of1.3 M MeLi in Et2O
(0.44 mL, 0.6 mmol) was added to a solution of 11b (32mg, 0.1 mmol) in THF (4 mL). The
reaction mixture was stirred at -78 oC for 30 min, then warmed up to 0 oC and stirred for 30 min.
The reaction was quenched with 0.1 M aq. HCl at 0 oC. The resulting mixture was extracted with
Et2O (3x). Organic layers were combined, dried over MgSO4, and concentrated under reduced
pressure to yield crude product 12 as a colorless oil (8 mg, 0.05 mmol, 50%). 1H NMR (300 MHz,
Chloroform-d) δ 6.90-6.35 (broad, 2H), 6.85 (m, 1H), 3.77 (t, J=6 Hz, 1H), 3.18 (d, J=9 Hz, 2H),
0.98 (s, 2H) ppm.

2-(pyridin-2-yldisulfaneyl)ethan-1-ol (33). 31 (0.175 mL, 2.5 mmol) and 32 (660 mg, 3.0
mmol) was added to MeOH (10 mL). The reaction mixture was stirred at room temperature for 2
h and then concentrated under reduced pressure to yield crude product. The crude product was
purified by flash chromatography (15/85 EtOAc/Hexanes) to yield 33 as slightly a yellow solid
(363 mg, 1.94 mmol, 80%). 1H NMR (300 MHz, Chloroform-d) δ 8.51 (ddq, J = 4.3, 1.7, 0.9 Hz,
1H), 7.59 (dddt, J = 8.1, 7.3, 1.6, 0.7 Hz, 1H), 7.40 (dp, J = 8.1, 1.0 Hz, 1H), 7.20 – 7.09 (m, 1H),
5.78 (t, J = 6.8 Hz, 1H), 3.80 (q, J = 5.7 Hz, 2H), 2.95 (ddt, J = 5.8, 4.0, 0.7 Hz, 2H) ppm.
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1,1,1,3,3,3-hexafluoro-2-(4-(N-(2,2,2-trifluoroethyl)phenylsulfonamido) phenyl)propan2-yl(2-(pyridin-2-yldisulfaneyl)ethyl) carbonate (37). DIEA (0.01 mL, 0.06 mmol), K2CO3 (3
mg, 0.024 mmol) and TO901317 (6 mg, 0.012 mmol) was added to CH2Cl2 (0.5mL) and the
mixture was cooled to -10oC. At -10oC, 0.24 mL of triphosgene solution (0.1M in CH2Cl2) was
added to the reaction mixture. The reaction mixture was stirred at -10oC for 1 hour and then
warmed up to room temperature. N2 was blew into the reaction vial to get rid of CH2Cl2 and
unreacted phosgene. CH2Cl2 (0.5 mL) and 36 (2 mg, 0.01 mmol) was added to the reaction. The
reaction mixture was stirred at room temperature for 2 h and then concentrated under reduced
pressure. The resulting material was purified by flash chromatography (10/90 EtOAc/Hexanes) to
yield 37 as a white solid (3 mg, 0.004 mmol, 43%). 1H NMR (300 MHz, Chloroform-d) δ 8.48 (dt,
J = 4.9, 1.4 Hz, 1H), 7.75 – 7.36 (m, 9H), 7.22 – 7.02 (m, 3H), 4.48 (t, J = 6.4 Hz, 2H), 4.24 (q, J
= 8.2 Hz, 2H), 3.10 (t, J = 6.4 Hz, 2H) ppm.

(11R,14S,17S,31S,35S)-14,17-dibenzyl-1,1,1-trifluoro-4,13,16,19,28,33-hexaoxo-2-(4-(N(2,2,2-trifluoroethyl)phenylsulfonamido)phenyl)-2-(trifluoromethyl)-3,5-dioxa-8,9-dithia12,15,18,27,32,34-hexaazaheptatriacontane-11,31,35,37-tetracarboxylic acid (39). 37 (9mg,
0.013 mmol) and 38 (9 mg, 0.01 mmol) was added to DMF/THF/H2O (0.4 mL/0.1 mL/0.1 mL).
The reaction mixture was stirred at room temperature overnight. The resulting mixture was loaded
on size exclusion chromatography to yield 39 as a white solid (5.5 mg, 0.004 mmol, 38%).
MALDI-MS calcd for C60H68F9N7O18S3 (Na+) 1464.35, found 1462.34. HPLC found only one
peak.
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APPENDIX B: NMR SPECTRA
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